Figure 10. The effect of anti IL-17A antibody administration on response to intranasal LVS infection.

(A) WT C57BL/6 mice were infected with 100 CFU (0.1×LD₅₀). Mice were then injected with 100 µg of neutralizing anti IL-17A mAb (n = 6 animals) or with carrier only (n = 10 animals) on days 0 and 7 post infection. (A1) depicts the cumulative survival of the two experimental groups, P value <0.05; (A2) depicts body weight monitoring of PBS-treated mice (gray diamonds), mAb-treated mice that eventually died (black squares, n = 4 animals) or recovered of the disease (white squares, n = 2 animals). Figure shows one experiment out of two performed (with similar results); (B) WT C57BL/6 mice were infected with 30 CFU. Mice were then injected with 100 µg of neutralizing anti IL-17A mAb (n = 10 animals) or with carrier only (n = 10 animals) on days 0 and 7 post infection. (B1) depicts the cumulative survival of the two experimental groups, P value <0.01; (B2) depicts body weight monitoring of PBS-treated mice (gray diamonds), mAb-treated mice that eventually died (black squares, n = 7 animals) or recovered of the disease (white squares, n = 3 animals). Figure shows one experiment out of two performed (with similar results). *denotes P value <0.05; ** denotes P value <0.01.